green tea + quercetin + docetaxel

This is an investigational combination therapy consisting of green tea (typically as a polyphenol extract, often with epigallocatechin gallate/EGCG as the main active component), quercetin (a flavonoid found in many fruits and vegetables), and the chemotherapeutic agent docetaxel. The rationale for this combination is to enhance the anti-cancer efficacy of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) by overcoming chemoresistance mechanisms. Preclinical studies show that green tea polyphenols and quercetin can sensitize prostate cancer cells to docetaxel by inhibiting cell proliferation, inducing apoptosis, enhancing cell cycle arrest at G2/M phase, downregulating multidrug resistance proteins such as MRP1 and P-glycoprotein, suppressing PI3K/Akt and STAT3 signaling pathways, reducing stem-like cell populations (CD44+/CD24−), inhibiting tumor invasion/colony formation, and reversing mesenchymal phenotypes[1][5][6]. Clinical trials are ongoing to evaluate safety and efficacy in mCRPC patients[2][3][4].

Other names

GT and Q + docetaxelgreen tea and quercetin plus docetaxel